Such conversations are becoming increasingly common as demand for weight-loss drugs explodes in urban India - a country with ...

Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.

Tirzepatide, a medication sold under the names Mounjaro for diabetes and Zepbound for weight loss, has shown impressive results in helping people avoid developing diabetes. A new study found that it ...

Novo Nordisk made a surprise bid for Metsera to boost its weight-loss market lead, trading at just 12x 2026 EPS. Read why NVO ...

Viking Therapeutics delivered a disappointing earnings report on October 22, revealing a quarterly loss of $0.81 per share that fell substantially short of ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker.

Plus, the Trump administration is expected to release finalized Medicare payment rules for doctors and hospitals as soon as next week.

Eli Lilly shares rise as Q3 revenue jumps 54% to $17.6 billion, earnings top estimates, and analysts lift price targets on ...

Wegovy Zepbound cost-effectiveness report finds both drugs remain valuable at higher prices despite affordability concerns, per ICER analysis.

This proprietary system employs specialized algorithms to identify early signs of litigation trends in federal litigation filings. Click here to learn more about Law.com Radar's new suit alerting and ...

Before being discontinued, the P2X7 receptor blocker had cleared a master protocol study in chronic pain, though Eli Lilly ...

TLDR Novo Nordisk launched an unsolicited $9 billion offer for Metsera, trumping Pfizer’s existing $7.3 billion acquisition ...